Drug Trial Radar · NCT01342081
DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5%
Last checked: Nov 20, 2026Latest source record: Jun 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
489
Actual
Start
May 2011
Primary completion
Sep 2012
Sponsor
- Lead sponsor
- Santen Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 26, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
Summary
As written by the sponsor on the registry.
DE-111 ophthalmic solution will be evaluated for superiority in comparison with Tafluprost 0.0015% ophthalmic solution, or for non-inferiority in comparison with Tafluprost 0.0015% and Timolol ophthalmic solution 0.5% used concomitantly, in IOP(intraocular pressure) -lowering effect in primary open-angle glaucoma or ocular hypertension patients, in a multicenter, randomized, double-masked, parallel-group comparison study. Safety will be compared and evaluated as well.
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
DE-111 ophthalmic solutionDrug
Tafluprost ophthalmic solution 0.0015%Drug
Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Diurnal IOP(Intraocular Pressure) at End of StudyTime frame: Week 0(Baseline) and Week 4(End of Study)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Santen study sites
Osaka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.